3o9b: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
 ==Crystal Structure of wild-type HIV-1 Protease in Complex with kd25==
-<StructureSection load='3o9b' size='340' side='right' caption='[[3o9b]], [[Resolution|resolution]] 1.50&Aring;' scene=''>
+<StructureSection load='3o9b' size='340' side='right'caption='[[3o9b]], [[Resolution|resolution]] 1.50&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[3o9b]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/9hiv1 9hiv1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O9B OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3O9B FirstGlance]. <br>
+<table><tr><td colspan='2'>[[3o9b]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3O9B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3O9B FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K2A:(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL+[(1S,2R)-1-BENZYL-2-HYDROXY-3-({[4-(HYDROXYMETHYL)PHENYL]SULFONYL}[(2S)-2-METHYLBUTYL]AMINO)PROPYL]CARBAMATE'>K2A</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.5&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3o99|3o99]], [[3o9a|3o9a]], [[3o9c|3o9c]], [[3o9d|3o9d]], [[3o9e|3o9e]], [[3o9f|3o9f]], [[3o9g|3o9g]], [[3o9h|3o9h]], [[3o9i|3o9i]]</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K2A:(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL+[(1S,2R)-1-BENZYL-2-HYDROXY-3-({[4-(HYDROXYMETHYL)PHENYL]SULFONYL}[(2S)-2-METHYLBUTYL]AMINO)PROPYL]CARBAMATE'>K2A</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">gag-pol, pol ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 9HIV1])</td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3o9b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9b OCA], [https://pdbe.org/3o9b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3o9b RCSB], [https://www.ebi.ac.uk/pdbsum/3o9b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3o9b ProSAT]</span></td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3o9b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3o9b OCA], [http://pdbe.org/3o9b PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3o9b RCSB], [http://www.ebi.ac.uk/pdbsum/3o9b PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3o9b ProSAT]</span></td></tr>
 </table>
-<div style="background-color:#fffaf0;">
+== Function ==
-== Publication Abstract from PubMed ==
+[https://www.uniprot.org/uniprot/Q90K99_9HIV1 Q90K99_9HIV1]
-The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhibitors within the consensus volume of natural substrates, providing inhibitors less susceptible to resistance because a mutation affecting such inhibitors will simultaneously affect viral substrate processing. The designed PIs share a common chemical scaffold but utilize various moieties that optimally fill the substrate envelope, as confirmed by crystal structures. The designed PIs retain robust binding to MDR protease variants and display exceptional antiviral potencies against different clades of HIV as well as a panel of 12 drug-resistant viral strains. The substrate envelope model proves to be a powerful strategy to develop potent and robust inhibitors that avoid drug resistance.
-Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.,Nalam MN, Ali A, Reddy GS, Cao H, Anjum SG, Altman MD, Yilmaz NK, Tidor B, Rana TM, Schiffer CA Chem Biol. 2013 Sep 19;20(9):1116-24. doi: 10.1016/j.chembiol.2013.07.014. Epub, 2013 Sep 5. PMID:24012370<ref>PMID:24012370</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 3o9b" style="background-color:#fffaf0;"></div>
-== References ==
-<references/>
 __TOC__
 </StructureSection>
-[[Category: Nalam, M N.L]]
+[[Category: Human immunodeficiency virus 1]]
-[[Category: Schiffer, C A]]
+[[Category: Large Structures]]
-[[Category: Aid]]
+[[Category: Nalam MNL]]
-[[Category: Aspartyl protease]]
+[[Category: Schiffer CA]]
-[[Category: Drug design]]
-[[Category: Drug resistance]]
-[[Category: Hiv-1 protease]]
-[[Category: Hydrolase-hydrolase inhibitor complex]]
-[[Category: Protease inhibitor]]